AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$BCDA

Altman Peter purchased $1K of BCDA

Altman Peter (President and CEO) purchased 1,000 shares of BioCardia, Inc. (BCDA) at $1.03 on 2026-09-29.

Original reporting
SEC EDGAR · Altman Peter
Published Sep 30, 2026, 10:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCDA
Neutral
low confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDANeutralLow
01

Why it matters

The transaction is too small to affect market pricing but confirms the CEO's continued ownership.

02

Market read

Limited relevance; likely no immediate trading opportunity.

03

What to watch

Potential upcoming corporate events or financing needs that prompted the insider to increase his stake.

Relevance 4/10Novelty 3/10Timing: after market close

Background

Form 4 filing discloses a $1,030 insider purchase by BioCardia's CEO.

Company-level read

Ticker impact

$BCDANeutralLow confidence
Context

CEO Altman Peter bought 1,000 shares at $1.03 each, total $1,030, increasing his stake to 384,885 shares.

Expected impact

minimal upward pressure as a confidence signal, but size is too tiny to move the stock.

Evidence & confidence

Insider buying by a CEO can be positive, yet $1k is trivial for a listed biotech; traders are unlikely to act.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The purchase may be a routine portfolio adjustment rather than a strong confidence signal.

Key entities

  • person
    Altman Peter

    President and CEO of BioCardia, Inc.

  • company
    BioCardia, Inc.

    US-listed biotech company (ticker BCDA).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCDA insider trading history →

Related articles

SEP 23
$BCDAMed

BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif. – September 23, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of ca

SEC EDGAR 8-K2 min
AUG 19
$BCDAMed

BioCardia (BCDA) Q2 2026 Earnings Call Transcript

BioCardia (BCDA) reported Q2 2026 earnings with $4.1M in cash, a net loss of $1.6M, and raised $4.9M via ATM facility. The company reduced R&D spending and is progressing with regulatory submissions for CardiAMP in Japan and the U.S. Management anticipates market approval in Japan by Q4 2027 and FDA premarket approval support from ongoing trials. BioCardia is also exploring partnerships and streamlining trials to enhance enrollment.

fool.com3 min
AUG 13
$BCDAMed

BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan

BioCardia (BCDA) reported Q2 2026 regulatory updates for its CardiAMP cell therapy and Helix delivery catheter. According to management, Japan’s PMDA supported a Shonin premarket submission, with approval expected about 12 months after filing. The FDA said CardiAMP Heart Failure 2 could support premarket approval and outlined two Helix clearance pathways. Q2 2026 net cash used in operations was ~$1.7M; cash ended at ~$5.4M.

yahoo.com4 min
AUG 12
$BCDAMed

BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results Sunnyvale, Calif. – August 12, 2026 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,

SEC EDGAR 8-K6 min